Name of study:
ASPEN: Evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations over the 52-week treatment period.
Non-Cystic Fibrosis Bronchiectasis
Purpose of study:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis
Is this a pre- or post- market study?:
Is the study of a controlled or observational design?
What is the funding source?:
Where is the study being conducted?
City and State:
When the study is being conducted:
End date: 3/31/2024
What website should a person use to register for the study?
Who should a person contact to register for the study?
Phone: (213) 549-2979
Email: [email protected]
Who is sponsoring this study?
What is the identifier for this study on ClinicalTrials.gov?
Page last updated: February 23, 2021